Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale RA’ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: “2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA™ ART100 system, including active clinical use at leading medical centers, advancement of...

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing...

HAUPPAUGE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG) today reported financial results for the fiscal year ended December 31, 2025, as included in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Strong Revenue Growth Driven by 5G and Core RF Product Demand Revenue increased to $25.2 million for fiscal year 2025, compared to $9.5 million in fiscal year 2024, representing growth of approximately 165% year-over-year. The increase was driven primarily by higher sales of low noise amplifier (LNA) and low noise block (LNB) products, expanded 5G product lines, and strong demand from telecommunications and satellite communications customers. The Spectrum division also benefited from a rebound in Asian markets. Gross Profit Expansion Reflects Strategic 5G Market Penetration Gross...

Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and...

Delivered first production powertrains for Blue Bird school buses Achieved third consecutive quarter of positive operating cash flow and free cash flow, ending 2025 with $14.0 million in cash — up 28% year-over-year Reduced full-year operating expenses by $14.0 million (28.2% YoY) and cut full-year EBITDA loss by more than half — from $42.2 million to $21.0 million LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading energy storage and fleet electrification solutions provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. Building on a year of disciplined execution and consistent operational improvement, Xos closed 2025 with its third consecutive quarter of positive operating cash flow and positive free...

$116.6 million stockholders’ equity as of December 31, 2025 NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq:VRM) today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. HIGHLIGHTS OF FOURTH QUARTER AND FULL YEAR 2025$116.6 million stockholders’ equity as of December 31, 2025 and $104.2 million tangible book value(1) as of December 31, 2025 $129.3 million improvement in net loss and $66.0 million improvement in adjusted net loss(2) for full year 2025 compared to 2024 $48.7 million consolidated total available liquidity(3) as of December 31, 2025, consisting of:$10.4 million cash and cash equivalents         $11.3 million of liquidity available to UACC under the warehouse credit facilities $27.0 million of available liquidity from delayed draw facility, further...

SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsFourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024. New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024. CapsoCam Plus® used by over 161,000 patients as of December 31, 2025. Submitted 510(k) application to the Food and Drug Administration (FDA) for its in-house developed AI-assisted module for...

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – – Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – – Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – – Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen – – Conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN JOSE, Calif., March 26, 2026 (GLOBE NEWSWIRE) —...

Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama. Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year. Increases quarterly dividend to $0.70 per share.ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth quarter of fiscal 2025 were $374 million compared to $391 million in the fourth quarter of fiscal 2024. Diluted loss per share on a GAAP basis...

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial HighlightsGenerated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarter Cyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarterSold 15,900 Cyclo G6 probes compared to 13,300 in the prior...